Treatment of Crohn’s disease of inflammatory, stenotic, and fistulizing phenotypes

  title={Treatment of Crohn’s disease of inflammatory, stenotic, and fistulizing phenotypes},
  author={Marla C. Dubinsky and Phillip Fleshner},
  journal={Current Treatment Options in Gastroenterology},
Opinion statementThe heterogeneous nature of Crohn’s disease (CD) is reflected in the diversity of treatment options available for individual patients. The stratification of CD patients into more homogeneous groups based on disease location and disease behavior may provide clinicians with a more focused approach to therapeutic decision-making. Uncomplicated disease behaviors are typically treated medically. When complications arise and patterns of disease become more aggressive, combined… 
Clinical Treatment in IBD
The goal of the treatment, especially maintenance therapy, in both UC and CD is to achieve and maintain a steroid-free remission, clinically and endoscopically defined.
Post-operative recurrence in Crohn's disease. Critical analysis of potential risk factors. An update.
Design and evaluation of fluorescent and non-fluorescent bivalent ligands to explore their mode of action at neuropeptide Y receptors
This thesis describes the design and synthesis of novel fluorescent and non-fluorescent derivatives of the cyclic peptide GR231118 and the study of their actions at the Y1 and the Y4 receptors, which improves understanding of the Y 1 and Y4 receptor pharmacology.


Long-Term Evolution of Disease Behavior of Crohn's Disease
Most patients with CD will eventually one day develop a stricturing or a perforating complication, and initial location determines the type of the complication.
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease and the most common adverse events for patients treated with infliximab were headache, abscess, upper respiratory tract infection, and fatigue.
A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
The aim of this international Working Party was to develop a simple classification of Crohn's disease based on objective variables, and the allocation of patients to these 24 subgroups proved feasible and resulted in specific disease clusters.
Combination ciprofloxacin and metronidazole for active Crohn's disease.
Ciprofloxacin in combination with metronidazole is well tolerated and appears to play a beneficial role in achieving clinical remission for patients with active Crohn's disease, particularly when there is involvement of the colon.
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease
Location of Crohn's disease, as defined by the Vienna classification, is a relatively stable phenotype which seems suitable for phenotype-genotype analyses and cannot be used in phenotype- genotype analyses.
Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
The addition of low-dose cyclosporine to conventional treatment for Crohn's disease did not improve symptoms or reduce requirements for other forms of therapy, and analyses of the meanCrohn's Disease Activity Index and quality-of-life scores and of the use of prednisone and 5-aminosalicylates also failed to demonstrate benefit.
Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease
Topical tacrolimus at low concentrations (0.5 mg/g) shows promise in the management of childhood perineal and oral Crohn's disease, with no evidence of significant systemic absorption, however, rapid weaning or abrupt cessation of therapy may cause rebound worsening of disease.
Crohn's disease: are enteroenteral fistulas an indication for surgery?
Patients who initially received nonoperative therapy and later required operation did not have any increased mortality or morbidity as compared with those treated with early surgery, and the natural history of enteroenteral fistulas was documented.
Oral Budesonide for Active Crohn's Disease
This double-blind, multicenter trial investigated the efficacy and safety of an oral controlled-ileal-release preparation of budesonide in patients with active Crohn's disease involving the ilesum or ileum and proximal colon and found remission occurred after eight weeks of treatment.